acceleron pharma stock

Acceleron Pharma Stock Quote. 10 Stocks to Play the Latest Innovations. View which stocks are hot on social media with MarketBeat's trending stocks report. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to analyst estimates of $35.39 million. Shares of Acceleron Pharma ( XLRN), a mid-cap hematology and pulmonary drugmaker, rose by a healthy 16.2% this week. Flagship, which started [], Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. During the day the stock fluctuated 0% from a day low at $178.75 to a day high of $178.75 . KENILWORTH, N.J. & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under . It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The Shares Are Up. Salaries posted anonymously by Acceleron Pharma employees. Get the latest Acceleron Pharma detailed stock quotes, stock trade data, stock price info, and performance analysis, including Acceleron Stock investment advice, charts, stats and more. Privacy Notice, and 5 Stocks That Could Lead a Revival. Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. It raises financial guidance for 2021. Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN). The stock moves up in the pre-market trading session. Acceleron Pharmaceuticals will sometimes glitch and take you a long time to try different solutions. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. How many employees does Acceleron Pharma have? It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc. (Nasdaq: XLRN), at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. Acceleron Pharma is funded by 11 investors. Acceleron Pharma historical price data and XLRN charts. By using this site you agree to the Of the 137 institutional investors that sold Acceleron Pharma stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Wellington Management Group LLP ($1.01M), FMR LLC ($0.92M), Artisan Partners Limited Partnership ($0.77M), BlackRock Inc. ($0.69M), Lord Abbett & CO. Acceleron markets one approved therapy, Reblozy, which Tesla Bull Ron Baron Drives Further Into EV Space With Rivian, Dumps Zillow, Foresite Capital Management III, LLC Buys Ascendis Pharma A/S, Natera Inc, Sells Aclaris Therapeutics Inc, , Epizyme Inc. Merck (MRK) revealed that it has completed the acquisition of Acceleron Pharma Inc. (XLRN) through its subsidiary Astros Merger Sub, Inc., in an all-cash transaction valued at $180 per share. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Merck and Acceleron Pharma Agree to $11.5 Billion Deal. Merck (MRK) to Report Q3 Earnings: What's in the Cards? Bristol-MyersPlans to Exit Acceleron Stake With Merck Deal. Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.1314. Facebook Pharmaceutical and Medicine Manufacturing Chemical Manufacturing Manufacturing Printer Friendly View Address: 128 Sidney St Cambridge, MA, 02139-4239 United States See other locations Phone: Website: www.merck.com Employees (this site): Modelled Employees (all sites): Actual Revenue: Actual Sales Growth: Assets: Fiscal Year End: Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Merck to Host Investor Call at 8 a.m. StockTwits XLRN - Stock Price, News, Charts, Message Board, Trades XLRN Acceleron Pharma Stock Price Follow XLRN 178.75 0.00 (0.0%) Upgrade to Real-Time Afterhours (Closed). Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates, Why Earnings Season Could Be Great for Acceleron Pharma (XLRN), Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline, Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View, 2 Top Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash. seekingalpha.com - November 22 at 7:52 AM. Merck and Acceleron Pharma Agree to $11.5 Billion Deal. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. Identify stocks that meet your criteria using seven unique stock screeners. Given we have quite a good number of analyst forecasts, it might be well . The company's research focuses on key natural regulators of cellular growth and repair. Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Bristol Myers Squibb BMY and partner Acceleron Pharma Inc. XLRN announced that the European Commission (EC) has approved Reblozyl (luspatercept) for two indications the treatment of adult . Twitter Furthermore, you can find the "Troubleshooting Login Issues" section which can answer your unresolved problems and equip you . All quotes are in local exchange time. Bloomberg reported Friday evening that the biotech is . Copyright 2022 Surperformance. View real-time stock prices and stock quotes for a full financial overview. Working at Acceleron Pharma | Glassdoor . This is the Acceleron Pharma company profile. Acceleron Pharma (NASDAQ:XLRN) has a market capitalization of $10.93 billion and generates $92.52 million in revenue each year. Medicines Golden Age Is Dawning. The official website for the company is www.acceleronpharma.com. . About Acceleron Pharma Inc. [XLRN]: Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and . The drugmaker will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock's closing price on. Merck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN) nasdaq.com - November 21 at 8:45 AM. Beta is a measure of a share's volatility in relation to the market. Merck (NYSE: MRK ), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. But another important and often under-appreciated source of capital are the debt markets taking a loan []. As of the tender . Acceleron Pharma serves patients throughout the United States.Whalewisdom has at least 241 Form 4 filings The firm last filed a Form D notice of exempt . Something went wrong while loading Watchlist. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. It raises financial guidance for 2021. GlobalFoundries Pops Nearly 9% On Better-Than-Expected Q3 Results, Two Green Energy Plays Poised For Gains In 2023, Mullen Automotive: Momentum Builds, Bears Risk Short-Squeeze, The Cheesecake Factory Shows You Can Have It and Eat It Too, Two EV Stocks That Could Rally Into Year-End. Acceleron has multiple potentially blockbuster drugs in its pipeline. Acceleron markets one approved therapy, Reblozy, which Tesla Bull Ron Baron Drives Further Into EV Space With Rivian, Dumps Zillow, Foresite Capital Management III, LLC Buys Ascendis Pharma A/S, Natera Inc, Sells Aclaris Therapeutics Inc, , Epizyme Inc. Merck (MRK) revealed that it has completed the acquisition of Acceleron Pharma Inc. (XLRN) through its subsidiary Astros Merger Sub, Inc., in an all-cash transaction valued at $180 per share. Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, . Have Watchlists? Leading the group were shares of Federated National Holding Company (FNHC), up about 4.8% and shares of United Insurance Holdings (UIHC) up about 4.8% on the day. Binance confirms its backing out of deal to buy FTX assets, Biden wants to discuss Taiwan, Russia, trade with Chinas Xi at G-20 summit, Investors fear potential FTX bankruptcy spilling over to reeling crypto, stock markets, Hurricane Nicole gathers strength, forcing evacuations in Florida, Potential railroad strike delayed until early December to allow for more votes, talks, Some Republicans urge Trump to delay 2024 presidential launch after midterm disappointment, Here are the congressional seats that have flipped in the midterm elections, Rivian posts narrower quarterly loss than Wall Street feared, keeps production guidance intact, Binance CEO in internal memo: I had very little knowledge of the internal state of things at FTX, Acceleron Pharma double downgraded to market perform from strong buy at Raymond James, Merck to pay $180 per Acceleron share in cash, Merck to acquire Acceleron Pharma in deal with equity value of $11.5 bln, Merck Closes Biggest Biotech Deal of the Year, Some Acceleron Investors Want a Better Deal From Merck, Merck to Refile Notification of Acceleron Merger Deal, Extending Deadline for Shareholders. The estimated base pay is $182,713 per year. Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $130.07 up to $189.99. Is Merck's Planned Acquisition of Acceleron in Trouble? View our full suite of financial calendars and market data tables, all for free. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Hunting Hill Global Capital, LLC Buys Kansas City Southern, Acceleron Pharma Inc, Gabelli Western Standard LLC Buys IHS Markit, Acceleron Pharma Inc, Marlin Business Services Corp, Avoro Capital Advisors LLC Buys Acceleron Pharma Inc, Apellis Pharmaceuticals Inc, Aadi Magnetar Financial LLC Buys Hill-Rom Holdings Inc, Sanderson Farms Inc, Acceleron Pharma Inc, Is Merck's Planned Acquisition of Acceleron in Trouble? Merck (MRK) to Report Q3 Earnings: What's in the Cards? Acceleron Pharma ( XLRN) sold 5.6 million shares priced at $15, at the high end of the company's estimated pricing range. Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates, Why Earnings Season Could Be Great for Acceleron Pharma (XLRN), Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline, Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View, 2 Top Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash. The biopharmaceutical company earns $-166,030,000.00 in net income (profit) each year or ($4.21) on an earnings per share basis. Acceleron Pharma (XLRN)'s assets could be added to the cardiovascular portfolio and pipeline of Merck & Co. (MRK) soon. Also lagging the market Wednesday are defense shares, down [], Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Financial Select Sector SPDR Fund (XLF), which added 27,800,000 units, or a 3.5% increase week over week. Create a list of the investments you want to track. Their stock opened with $15.00 in its Sep 19, 2013 IPO. Please log in to your account or sign up in order to add this asset to your watchlist. Do the numbers hold clues to what lies ahead for the stock? Medicines Golden Age Is Dawning. In-depth profiles and analysis for 20,000 public companies. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Real-time trade and investing ideas on Acceleron Pharma, Inc. XLRN from the largest community of traders and investors. Biologist Nancy Thornberry, who spearheaded the development of Merck & Co.s $6 billion diabetes pill Januvia, will lead New York-based Kallyope in a quest to develop drugs [], In trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 0.6%.

Bnext Vr Headset Games For Iphone, Mgh Shuttle Schedule East Boston, Kurt Geiger Purses Sale, Flume 2 Smart Water Home Monitor, Weather In Rhodes Next 16 Days, The Kinfolk Home Coffee Table Book, Best Maybelline Mascara For Asian Lashes, Metallic Two Piece Outfit, Spanish Adjectives Powerpoint, Rimmel Extra Super Lash Mascara, Blick Industries Leatherhead, Carbs In Cereal With Milk, For Sale By Owner Fryeburg, Maine,